Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis.

Abstract:

OBJECTIVE:Permanent polymer drug-eluting stents (DES) are associated with a higher risk of late and very late stent thrombosis (ST); biodegradable polymer drug-eluting stents (BP-DES) were designed to reduce these risks. However, their benefits are not completely clear. METHOD:We undertook a meta-analysis of randomized studies identified in systematic searches of MEDLINE, EMBASE, and the Cochrane Database. Eligible studies were those that compared BP-DES with second-generation permanent polymer DES in patients undergoing percutaneous coronary intervention. RESULTS:Five studies (8,740 patients) with a mean follow-up of 19.2 months were included. Overall, BP-DES were associated with a broadly equivalent risk of definite and probable ST (odds ratio [OR], 1.07; 95 % confidence interval [CI], 0.67 to 1.71; P = 0.76; I (2) = 5.0 %), target vessel revascularization (OR, 1.04; 95 % CI, 0.87 to 1.24; P = 0.68; I (2) = 38.0 %), all-cause mortality (OR, 1.10; 95 % CI, 0.87 to 1.41; P = 0.42; I (2) = 0.0 %), and major adverse cardiac events (OR, 1.03; 95 % CI, 0.88 to 1.20; P = 0.74; I (2) = 0.0 %) when compared with second-generation DES. However, BP-DES significantly decreased in-stent late luminal loss (standard mean difference [SMD], -0.01; 95 % CI, -0.12 to 0.11; P = 0.93; I (2) = 0.0 %) and in-segment late luminal loss (SMD, -0.06; 95 % CI, -0.17 to 0.05; P = 0.27; I (2) = 0.0 %) compared with second-generation DES. CONCLUSIONS:Compared with second-generation permanent polymer DES, biodegradable stents appear to have equivalent short- to medium-term clinical benefits, and it remains unclear whether they reduce the incidence of very late ST.

journal_name

Cardiovasc Drugs Ther

authors

Wang Y,Dong P,Li L,Li X,Wang H,Yang X,Wang S,Li Z,Shang X

doi

10.1007/s10557-014-6528-7

subject

Has Abstract

pub_date

2014-08-01 00:00:00

pages

379-85

issue

4

eissn

0920-3206

issn

1573-7241

journal_volume

28

pub_type

杂志文章,meta分析
  • Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.

    abstract::The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of lef...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007713118941

    authors: Sheiban I,Tonni S,Chizzoni A,Marini A,Trevi G

    更新日期:1997-03-01 00:00:00

  • Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.

    abstract:AIMS:Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07103-9

    authors: Lévy S,Hartikainen J,Ritz B,Juhlin T,Carbajosa-Dalmau J,Domanovits H

    更新日期:2020-11-18 00:00:00

  • Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.

    abstract:BACKGROUND:Heart failure (HF) is considered to be a prothrombotic condition and it has been suggested that coagulation factors contribute to maladaptive cardiac remodelling via activation of the protease-activated receptor 1 (PAR1). We tested the hypothesis that anticoagulation with the factor Xa (FXa) inhibitor apixab...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06999-7

    authors: Yurista SR,Silljé HHW,Nijholt KT,Dokter MM,van Veldhuisen DJ,de Boer RA,Westenbrink BD

    更新日期:2020-05-26 00:00:00

  • Cardiac metabolism and mechanics are altered by genetic loss of lipoprotein triglyceride lipolysis.

    abstract:INTRODUCTION:Most circulating fatty acids are contained in lipoprotein triglycerides. For the heart to acquire these lipids, they must be broken down into free fatty acids via the enzyme lipoprotein lipase (LpL). Although it has long been known that hearts primarily use esterified fatty acids as fuel, different sources...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-006-0633-1

    authors: Noh HL,Yamashita H,Goldberg IJ

    更新日期:2006-12-01 00:00:00

  • The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species.

    abstract:PURPOSE:The melatonin receptor (MT) agonist ramelteon has a higher affinity to MT1 than for MT2 receptors and induces cardioprotection by involvement of mitochondrial potassium channels. Activation of mitochondrial potassium channels leads to release of free radicals. We investigated whether (1) ramelteon-induced cardi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06972-4

    authors: Stroethoff M,Goetze L,Torregroza C,Bunte S,Raupach A,Heinen A,Mathes A,Hollmann MW,Huhn R

    更新日期:2020-06-01 00:00:00

  • Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?

    abstract::In order to compare and clarify the effects of various antiarrhythmic drugs when given as monotherapy, we reevaluated our previous data on antiarrhythmic drugs and recalculated antiarrhythmic plasma concentrations of drugs for several canine arrhythmia models. We used three spontaneously occurring arrhythmias: a) digi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00120829

    authors: Hashimoto K,Haruno A,Matsuzaki T,Sugiyama A,Akiyama K

    更新日期:1991-08-01 00:00:00

  • Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

    abstract:BACKGROUND:The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting. METHODS:Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induc...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06954-6

    authors: Yurista SR,Silljé HHW,van Goor H,Hillebrands JL,Heerspink HJL,de Menezes Montenegro L,Oberdorf-Maass SU,de Boer RA,Westenbrink BD

    更新日期:2020-06-01 00:00:00

  • Cholesterol confusion in primary prevention of coronary artery disease.

    abstract::Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/BF00878930

    authors: Opie LH

    更新日期:1993-11-01 00:00:00

  • Incremental "Therapeutic" Myocardial Exposure to Catecholamines: Incidence and Impact in Takotsubo Syndrome.

    abstract:BACKGROUND:Although Takotsubo syndrome (TS) was once considered to be rare and largely benign, it is now recognized to represent a major cause of cardiac morbidity and mortality, especially in ageing women. The biochemical precipitant of attacks of TS is an increase in catecholamine concentrations within the myocardium...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06918-5

    authors: Ong GJ,Nguyen TH,Stansborough J,Surikow SY,Horowitz JD

    更新日期:2020-02-01 00:00:00

  • OPC-8212 in the treatment of congestive heart failure: results of a pilot study.

    abstract::To characterize the effects of OPC-8212, a quinolone inotropic agent, in patients with heart failure, we utilized invasive hemodynamics, exercise testing, 24-hour ambulatory electrocardiograms, and two patient self-assessment questionnaires, before and after 1 month of treatment with OPC-8212, in 17 patients with mode...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00054205

    authors: Kubo SH,Rector TS,Strobeck JE,Cohn JN

    更新日期:1988-12-01 00:00:00

  • Inhibition of phosphodiesterases leads to prevention of the mitochondrial permeability transition pore opening and reperfusion injury in cardiac H9c2 cells.

    abstract:PURPOSE:We tested if inhibition of phosphodiesterases (PDEs) with IBMX (1-methyl-3-isobutylxanthine) can modulate the mitochondrial permeability transition pore (mPTP) opening by inactivating glycogen synthase kinase 3β (GSK-3β). METHODS:H9c2 cells were exposed to 600 μM H(2)O(2) for 20 min to cause the mPTP opening. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-011-6310-z

    authors: Chanoit G,Zhou J,Lee S,McIntosh R,Shen X,Zvara DA,Xu Z

    更新日期:2011-08-01 00:00:00

  • Older statin initiators in Finland - cardiovascular risk profiles and persistence of use.

    abstract:PURPOSE:The benefits of statin treatment initiated in advanced age are largely unknown; however, good adherence to treatment is essential for beneficial effects to be achieved also when treating older people. This study characterizes older statin initiators, including their cardiovascular risk profiles and morbidity, a...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-014-6517-x

    authors: Upmeier E,Korhonen MJ,Rikala M,Helin-Salmivaara A,Huupponen R

    更新日期:2014-06-01 00:00:00

  • Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.

    abstract:PURPOSE:In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adul...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-014-6516-y

    authors: Rosenson RS,Rigby SP,Jones MR,Chou HS

    更新日期:2014-06-01 00:00:00

  • Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.

    abstract::Pulmonary arterial hypertension is a rare disease, with drug-induced causes even more uncommon, accounting for only 10% of cases in large registry series. Predisposing factors for drug-induced PAH have not been completely defined. This review summarizes drugs with definite, possible, or likely association to pulmonary...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-019-06920-x

    authors: Correale M,Tricarico L,Grazioli D,Formica ES,Petrucci R,Persichella P,Di Biase M,Brunetti ND

    更新日期:2019-12-01 00:00:00

  • Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

    abstract::Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebo-controlled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878092

    authors: Kuhn A,Carlsson J,Miketic S,Tebbe U

    更新日期:1995-08-01 00:00:00

  • Calcium antagonists and myocardial infarction.

    abstract::In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029738

    authors: Hansen JF

    更新日期:1991-08-01 00:00:00

  • Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure.

    abstract::Heart rate variability is a noninvasive indicator of autonomic nervous system activity. The role of the autonomic nervous system in the genesis of atrial or ventricular arrhythmias is now well established. Little is known about the effects of flecainide on heart rate variability in patients with normal heart structure...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007710301259

    authors: Fauchier L,Babuty D,Autret ML,Poret P,Cosnay P,Fauchier JP

    更新日期:1998-10-01 00:00:00

  • Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.

    abstract::The antihypertensive effects of once-daily administration of celiprolol 400 mg were compared with those of once-daily enalapril 20 mg in 20 mild to moderate essential hypertensives in a single-blind study in which the subjects were randomized to 2 weeks' treatment with either drug, preceded by 2 weeks of placebo admin...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00051236

    authors: Ghiringhelli S,Cozzi E,Tsialtas D

    更新日期:1988-07-01 00:00:00

  • Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.

    abstract::Inhibition of the renin-angiotensin system has been a highly successful therapeutic approach for the prevention of hypertension-related end organ damage. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers lower blood pressure and reduce morbidity and mortality in patients with cardiovascular...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-010-6278-0

    authors: Siragy HM

    更新日期:2011-02-01 00:00:00

  • Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.

    abstract:BACKGROUND:Recent studies in rabbits have demonstrated that platelet P2Y12 receptor antagonists are cardioprotective, and that the mechanism is surprisingly not related to blockade of platelet aggregation but rather to triggering of the same signal transduction pathway seen in pre- and postconditioning. We wanted to de...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-012-6436-7

    authors: Yang XM,Liu Y,Cui L,Yang X,Liu Y,Tandon N,Kambayashi J,Downey JM,Cohen MV

    更新日期:2013-04-01 00:00:00

  • Heart Failure in Women--Insights from the Framingham Heart Study.

    abstract::In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50% dying within 5 years after onset...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-015-6599-0

    authors: Kenchaiah S,Vasan RS

    更新日期:2015-08-01 00:00:00

  • Can Clinical and Functional Outcomes Be Improved with an Intelligent "Internet Plus"-Based Full Disease Cycle Remote Ischemic Conditioning Program in Acute ST-elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention? Rational

    abstract:BACKGROUND:Acute ST-elevation myocardial infarction (STEMI) is associated with a high incidence of complications as well as a considerable hospitalization rate and economic burden. Preliminary evidence suggests that remote ischemic conditioning (RIC) is a promising non-invasive intervention that may effectively and saf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07022-9

    authors: Zheng Y,Reinhardt JD,Li J,Hu D,Lin S,Wang L,Dai R,Fan Z,Ding R,Chen L,Yuan L,Xu Z,Cheng Y,Yan C,Zhang X,Wang L,Zhang X,Teng M,Yu Q,Yin A,Lu X,i-RIC Trial Collaboration Group.

    更新日期:2020-06-30 00:00:00

  • A systemic combination therapy with granulocyte-colony stimulating factor plus erythropoietin aggravates the healing process of balloon-injured rat carotid arteries.

    abstract:OBJECTIVE:Percutaneous vascular interventions lead inevitably to a destruction of the endothelial lining at the site of injury. There are conflicting data on the therapeutic benefit of hematopoietic growth factors aiming at mobilisation of circulating endothelial cells to accelerate the reendothelialisation process. Ai...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-008-6117-8

    authors: Hack M,Mascha FG,Jobst BJ,Riegger GA,Griese DP

    更新日期:2008-10-01 00:00:00

  • Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.

    abstract:PURPOSE:Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06868-y

    authors: Hoenicka M,Golovchenko S,Englert L,Spaeth M,Shoshiashvili L,Großer C,Hofmann HS,Ried M

    更新日期:2019-06-01 00:00:00

  • Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.

    abstract::Colesevelam hydrochloride (colesevelam) is a novel, potent, bile acid-binding agent that has been shown to lower LDL cholesterol a mean of 19% at a dose of 3.8 g/d. We studied the pharmacokinetics of colesevelam coadministered with six drugs: digoxin and warfarin, agents with narrow therapeutic indices; sustained-rele...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1007831418308

    authors: Donovan JM,Stypinski D,Stiles MR,Olson TA,Burke SK

    更新日期:2000-12-01 00:00:00

  • A comparison of the effects of captopril and flosequinan in patients with severe heart failure.

    abstract::Angiotensin converting enzyme inhibitors have greatly improved the treatment of patients with chronic heart failure but they are not effective in all patients, and their use may be limited by side effects. There is, therefore, a need to investigate new drugs and to compare their efficacy with angiotensin converting en...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00055602

    authors: Cowley AJ,Wynne RD,Swami A,Birkhead J,Skene A,Hampton JR

    更新日期:1992-10-01 00:00:00

  • PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.

    abstract:BACKGROUND:Markers of thrombosis, inflammation, endothelial dysfunction and neurohumoral activation such as fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A are reported to be linked to the increase of cardiovascular risk for atherosclerosis progression and...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1024394610648

    authors: Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators.

    更新日期:2003-01-01 00:00:00

  • Left ventricular mass changes with nicardipine therapy in essential hypertension.

    abstract::Eighteen hypertensive patients (13 males, 5 females; age 48 +/- 13; diastolic blood pressure greater than 95 mmHg), either previously untreated or who had been off treatment for more than 3 months, underwent M-mode echocardiography before (DO) and after (D90) 3 months of nicardipine therapy (60-90 mg/day). All echocar...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01865511

    authors: Gosse P,Lacroix P,Roudaut R,Dallocchio M

    更新日期:1989-08-01 00:00:00

  • Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function.

    abstract::Twenty-nine patients with severe heart failure (NYHA III) were randomly assigned to receive therapy with an angiotensin converting enzyme inhibitor (ACE inhibitor), either captopril or enalapril. The mean daily dosage of captopril was 56 +/- 5 mg and of enalapril 9.5 +/- 0.4 mg. After a mean of 8 +/- 1 days, the influ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00054567

    authors: Osterziel KJ,Dietz R,Harder K,Kübler W

    更新日期:1992-04-01 00:00:00

  • Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy.

    abstract:PURPOSE:To assess the effects of electro-acupuncture (EA) on glycemic control, myocardial inflammation, and the progression of diabetic cardiomyopathy in mice with type 2 diabetes. METHODS:Db/Db mice received EA at PC6+ST36 (DM-Acu), non-acupoint simulation (DM-Sham), or no treatment (DM). EA was applied for 30 min pe...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07043-4

    authors: Ye Y,Birnbaum Y,Widen SG,Zhang Z,Zhu S,Bajaj M,Chen H

    更新日期:2020-12-01 00:00:00